Its opioid dissed by FDA advisors, S.F. drugmaker abandons program

The drug would have been the first new opioid in its class in more than 50 years.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.